en · de · es · fr · pt
analytical-notes.peptides6823.com › Topic › Background And Molecular Design — 2026 Update

Background And Molecular Design — 2026 Update

By Editorial Desk · published 2026-04-06 · last reviewed 2026-05-12 · Topic

cjc-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-05-12. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Design

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Structure And Receptor Pharmacology

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

Cjc-1295 at a glance

PropertyValueNotes
Peptide classSynthetic GHRH analogueBuilt on a 29 residue sequence
Primary targetGHRH receptor (GHRHR)Class B G protein coupled receptor
Unconjugated half lifeMinutesLimited by protease degradation
Key modificationFour residue substitutionsPositions 2, 8, 15 and 27
Common synonymModified GRF(1-29)Usually denotes the form without DAC

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Related pages on this site

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

Background from the literature

On June 7, 2021, the first-look images for the character of Soldier Boy were revealed through Twitter, which were followed by the first look images of the character of Crimson Countess released on November 5, 2021. The first footage of the season was unveiled on January 7, 2022, shortly after the release of Seven on 7's last episode which was released the same day. It was followed by the release of the season first poster which was released on March 10, consisting of Butcher's eyes glowing red. It was followed by the release of a red band teaser trailer just two days later. Alexandra Del Rosario from Deadline said that the trailer brought suspense by teasing what is coming to the season while also offering "plenty of gore in store for The Boys fans". Vlada Gelman writing for TVLine considered the trailer to be "jam-packed". Indie Wire's Samantha Bergerson deemed that the teaser offers a "bevy of blood, guts, and tears as humans and supes alike battle it out", even if it doesn't include any dialogue. During the course of a week, it was confirmed that the trailer was flagged more than 20 million times due to its graphic content. The official trailer was officially released on May 16. Pete Volk of the Polygon considered that the trailer offer glimpses of "Homelander's press tour after the events of season", as well as more details regarding Soldier Boy and the expected amount of blood for the season.

== Prevention == Hypervitaminosis A can be prevented by not ingesting more than the US Institute of Medicine Daily Tolerable Upper Level of intake for Vitamin A. This level is for synthetic and natural retinol ester forms of vitamin A. Carotene forms from dietary sources are not toxic. Possible pregnancy, liver disease, high alcohol consumption, and smoking are indications for close monitoring and limitation of vitamin A administration.

In the 2025 speculative fiction novel The Strange Case of Jane O. by Karen Thompson Walker, a New York City psychiatrist treats a hyperthymestic woman who has mysterious blackouts and hallucinations. In the 2025 romance novel The Survivor Wants to Die at the End by Adam Silvera, one of the protagonists, Alano Rosa, has hyperthymesia and can remember even before he was born. He relives every moment he remembers including feelings, which in some instances cause him physical pain.

Sources: en.wikipedia.org

Further detail

==== Interaction with the GTPase Associated Center ==== The GTPase Associated Center (GAC) is a region on the large ribosomal subunit that consists of two smaller regions of 23S ribosomal RNA called the L11 stalk and the sarcin-ricin loop (SRL). As a highly conserved rRNA loop in evolution, the SRL is critical in helping GTPases bind to the ribosome, but is not essential for GTP hydrolysis. There is some evidence to support that a phosphate oxygen in the A2662 residue of the SRL may help hydrolyze GTP.

=== Metabolism interactions === Grapefruit–drug interactions that affect the pre-systemic metabolism (i.e., the metabolism that occurs before the drug enters the blood) of drugs have a different duration of action than interactions that work by other mechanisms, such as on absorption, discussed below. The interaction is greatest when the juice is ingested with the drug or up to four hours before the drug. The location of the inhibition occurs in the lining of the intestines, not within the liver. The effects last because grapefruit-mediated inhibition of drug metabolizing enzymes, like CYP3A4, is irreversible; that is, once the grapefruit has "broken" the enzyme, the intestinal cells must produce more of the enzyme to restore their capacity to metabolize drugs that the enzyme is used to metabolize. It takes around 24 hours to regain 50% of the cell's baseline enzyme activity and it can take 72 hours for the enzyme activity to completely return to baseline. For this reason, simply separating citrus consumption and medications taken daily does not avoid the drug interaction.

==== International ==== 4-AcO-DMT is not scheduled under any international drug schedules, including the United Nations 1971 Convention on Psychotropic Substances, making it a potentially more accessible alternative to psilocybin for research.

Sources: en.wikipedia.org

Supporting material

After military leaders are assassinated, Gunnery Sergeant Brandon Beckett receives word that his father is one. Attempting to track down the assassin, Brandon finds out that his father is not dead, realizing that he is being used as bait.

In the Crimean war (1853–1856), mustard poultices were used for chest and abdominal complaints, including dysentery and cholera. During the American Civil War (1861–1865), poultices were applied to wounds when antiseptics such as iodine were unavailable. Honey-based poultices were used to aid wound healing during the world wars, taking advantage of honey's antimicrobial properties. Decline and survival in traditional medicine

Jim Reid – vocals, guitar, bass, synthesizers (1983–1999, 2007–present) William Reid – guitar, bass, vocals, synthesizers (1983–1999, 2007–present) Mark Crozer – rhythm guitar (2007–2008, 2012), bass (2013–present), backing vocals (2007–2008, 2012–present) Scott Von Ryper – guitar, backing vocals (2015–present) Justin Welch – drums (2021–present) Former members

Hemp juice is produced in a patented industrial procedure directly following harvest whereby the leafy upper part of the plant, including the flower heads, are being cold-pressed after harvest. These parts of the hemp plant have been entirely neglected so far in industrial hemp fabric production. Hence, through the procedure of pressing juice, a previously neglected highly valuable part of the plant is now being used for human consumption. All active ingredients remain fully intact without drying the hemp. The juice does not compete with the production of fibers and shives instead both add up to double revenue of the farmer. The average yield of hemp juice is approximately 3 tons per hectare. This newly developed production procedure allows for a significantly higher financial efficiency as well as sustainability in the cultivation of drug-free industrial hemp. Furthermore, the cold-pressing procedure preserves all of the plant-based active ingredients. There are two common harvesting procedures: "Cutting" the upper parts of the hemp plant or "stripping" the leaves off the uppermost part of the hemp plant. Both these procedures result in varying quantities of cannabinoids in the hemp juice. Consequently, the harvesting procedure in itself already influences the quality of the resulting hemp juice. If one only uses the uppermost, leafy part of the hemp plant for hemp juice production, the remaining part of the hemp plant can still be used for the industrial production of its fibers or any other industrial uses.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

What does the acronym DAC refer to?

DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.

Does this peptide occur naturally in the body?

No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

Network